Company intelligence / Profile preview

Distalmotion

Epalinges, Vaud, Switzerland

Ownership: Private
Development stage: Commercial

Overview

Distalmotion has developed the Dexter robotic surgery system to integrate the benefits of laparoscopy and robotics. The device received CE mark in Europe in 2020 for urology, gynecology, and general surgery. It received FDA De Novo authorization for inguinal hernia repair in Q4 2024. Over 1,500 clinical cases have been completed to date across Europe and the US. The company recently completed its first commercial sale of Dexter in the United States to Memorial Hermann Health System.

Therapeutic areas: OtherMen's HealthGastroenterologyWomen's Health
Modalities: DeviceRobotic surgical system
Industry: Surgical Medical Devices

Partnerships

Leading European hospitals as early adopters and training partnersMemorial Hermann Health System as first US customer

Beyond the preview

Go deeper on Distalmotion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Distalmotion.

Explore the full profile